Climb Bio’s (CLYM) “Buy” Rating Reiterated at B. Riley Financial

B. Riley Financial restated their buy rating on shares of Climb Bio (NASDAQ:CLYM) in a research note released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock, up from their previous price target of $26.00.

Several other equities research analysts have also recently issued reports on the company. Guggenheim assumed coverage on Climb Bio in a report on Monday, June 8th. They issued a “buy” rating and a $35.00 price objective on the stock. B Riley restated a “buy” rating on shares of Climb Bio in a research report on Friday. Royal Bank Of Canada started coverage on Climb Bio in a research note on Monday, August 3rd. They issued an “outperform” rating and a $23.00 price target on the stock. Truist Financial boosted their price target on Climb Bio from $17.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Piper Sandler set a $40.00 price objective on Climb Bio and gave the company an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.92.

Climb Bio Stock Performance

NASDAQ:CLYM opened at $15.52 on Friday. The company has a fifty day moving average of $14.04 and a two-hundred day moving average of $10.82. The stock has a market capitalization of $891.47 million, a PE ratio of -18.70 and a beta of 0.09. Climb Bio has a fifty-two week low of $1.54 and a fifty-two week high of $18.33.

Climb Bio (NASDAQ:CLYM) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03. Research analysts forecast that Climb Bio will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC purchased a new stake in shares of Climb Bio in the first quarter valued at approximately $27,000. Goldman Sachs Group Inc. acquired a new position in Climb Bio during the first quarter worth $147,000. Marshall Wace LLP purchased a new stake in Climb Bio in the 2nd quarter valued at $46,000. Qube Research & Technologies Ltd purchased a new stake in Climb Bio in the 2nd quarter valued at $43,000. Finally, Jane Street Group LLC acquired a new stake in shares of Climb Bio in the 2nd quarter worth $184,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Key Climb Bio News

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Encouraging CLYM116 data: Climb Bio reported that a single 320 mg dose of CLYM116 produced an approximately 29-day half-life, near-complete APRIL suppression, and 60%–75% reductions in IgA and Gd-IgA1 through 12 weeks. The drug was generally well tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia reported. The data support convenient once-every-12-weeks dosing for IgA nephropathy. Climb Bio CLYM116 Phase 1 Data
• Positive Sentiment: Analyst targets moved substantially higher: B. Riley reaffirmed a Buy rating and raised its price target to $30 from $26. BTIG lifted its target to $32 from $20 and maintained a Buy rating, while Baird raised its target to $25 from $21 and rated the shares Outperform. These revisions indicate analysts see greater commercial and competitive potential for CLYM116.
• Positive Sentiment: Wedbush described the Phase 1 results as positive, while Oppenheimer said the data could demonstrate a competitive position in the IgA nephropathy market. Wedbush Climb Bio Phase 1 Analysis
• Neutral Sentiment: The Phase 2 NAVIGATE-2 trial is ongoing, with initial data expected in the first half of 2027 and a potential Phase 3 start in 2027. Those milestones could provide more meaningful evidence of efficacy, but they also leave significant clinical and execution risk ahead.
• Negative Sentiment: Despite the favorable safety and biomarker results, reports noted that the stock slipped as investors digested the early-stage nature of the data. Phase 1 results do not establish that CLYM116 improves patient outcomes, and the shares’ large prior rally may be encouraging some profit-taking or demanding stronger evidence before advancing further. Climb Bio Slips After Early-Stage Trial Data

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.